Lina Gugucheva has served as Chief Business Officer of NewAmsterdam Pharma, a Phase 3 clinical-stage pharmaceutical company focused on the research and development of transformative therapies for metabolic diseases, since May 2021. Ms. Gugucheva is an experienced biotechnology executive with over a decade of business development, finance and strategy experience in the sector. She has led venture and private equity financings in excess of $300 million as well as M&A and strategic transactions totaling over $2.5 billion in potential returns. Ms. Gugucheva previously served as Chief Business Officer at Scorpion Therapeutics, Chief Business Officer at Northern Biologics (2020 sale to Boehringer Ingelheim), and VP of Business Development & Strategy at IFM Therapeutics (2019 subsidiary sale to Novartis; 2017 subsidiary sale to Bristol-Myers Squibb). Ms. Gugucheva began her career as a life sciences transactional attorney at the law firm of Covington & Burling and also served in-house at Royalty Pharma. Ms. Gugucheva holds a J.D. from Harvard Law School and a B.A. in molecular biology and political science from New York University.